Related Experiment Video
Updated: May 4, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes
Aleksandar Savic1, Dragomir Marisavljevic, Vanja Kvrgic
1Clinic of Hematology, Clinical Center of Vojvodina, University of Novi Sad, Novi Sad, Serbia.
Abstract:
The objective of this study is to externally validate the recently published Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome (MDS) and compare it with the International Prognostic Scoring System (IPSS). We conducted a retrospective study of 173 adult MDS patients who had not received disease-altering treatment. Using the Cox hazard method, we found the IPSS-R to be a significant predictor of survival (p < 0.001, hazard ratio, HR = 1.82, 95% confidence interval, CI 1.57-2.12) and time to acute myeloid leukemia (AML; p < 0.001, HR = 2.05, 95% CI 1.55-2.70). The IPSS-R has greater prognostic power for survival and time to AML compared with the IPSS, given higher Somers' D values (0.41 vs. 0.39 and 0.55 vs. 0.53, respectively). Using the log-rank test, we found a significant difference when comparing IPSS-R groups (p < 0.02), with the exception of the high-risk versus very high-risk group comparison. The IPSS-R reclassified low-risk and intermediate-1 IPSS groups into four groups (log-rank, p < 0.001) and intermediate-2 and high-risk IPSS groups into three groups (log-rank, p < 0.04, excluding high-risk vs. very high-risk comparison). We conclude that the IPSS-R has significant prognostic utility for MDS patients.
Insights
The Revised International Prognostic Scoring System (IPSS-R) accurately predicts survival and acute myeloid leukemia (AML) risk in myelodysplastic syndrome (MDS) patients, outperforming the older IPSS system.
Area of Science:
- Hematology
- Oncology
- Clinical Prognostics
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Accurate prognostication is crucial for guiding treatment decisions in MDS.
- The International Prognostic Scoring System (IPSS) has been a standard, but newer systems aim for improved accuracy.
Purpose of the Study:
- To externally validate the Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome (MDS).
- To compare the prognostic performance of IPSS-R against the International Prognostic Scoring System (IPSS).
Main Methods:
- Retrospective analysis of 173 adult MDS patients without prior disease-altering treatment.
- Utilized Cox hazard modeling to assess survival and time to acute myeloid leukemia (AML).
- Employed log-rank tests and Somers' D statistics for comparative analysis of prognostic scoring systems.
Main Results:
- IPSS-R significantly predicted survival (HR=1.82) and time to AML (HR=2.05) in MDS patients (p < 0.001 for both).
- IPSS-R demonstrated superior prognostic power over IPSS for survival and time to AML (higher Somers' D values).
- IPSS-R reclassified patient risk groups more granularly than IPSS, with significant differences observed (p < 0.02).
Conclusions:
- The IPSS-R is a validated and significant prognostic tool for MDS patients.
- IPSS-R offers improved prognostic utility compared to the IPSS for predicting outcomes.
- This scoring system aids in risk stratification and clinical decision-making for MDS management.
More Related Videos
12:05Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018